Tradingprofit Trading profit increased by $73m 46% to $233m from $160m in 2009 and trading profit margin increased from 18.9% to 25.6%.
The settlement in the year with the vendors of BlueSky Medical Group, Inc with regard to legal expenses in defending our NPWT intellectual property position increased trading profit by $25m.
During the year, Advanced Wound Management also benefited from a full years production at the new manufacturing facilityin China, reducing manufacturing costs.
Operatingprofit Operating profit increased by $76m to $220m.
This comprises the increase in trading profit of $73m and a reduction of $6m in restructuring and rationalisation costs partially offset by an increase of $3m in the amortisation of acquisition intangibles following the acquisition of Nucryst in December 2009.
2009 YEAR The following discussion and analysis is based upon, and should be read in conjunction with, the Group Accounts of Smith & Nephew included elsewhere in this Annual Report.
Financial Highlights of 2009 Group revenue was $3,772m for the year ended 31 December 2009, representing a 1% decline compared to 2008.
Unfavourable currency translation of -3% was partly offset by underlying revenue growth of 2%.
Profit before taxation was $670m in 2009, compared with $564m in 2008.
Attributable profit was $472m compared with $377m in 2008.
Adjusted attributable profit calculated as set out in Selected Financial Data, rose 18% to $580min 2009, from$493min 2008.
Basic earnings per Ordinary Share were 53.4, compared to 42.6 for 2008.
EPSA as set out in Selected Financial Data was 65.6 in 2009compared, to 55.6for2008, representing an 18% increase.
Fiscal 2009 Compared with Fiscal 2008 The followingtable sets out certain income statement data forthe periods indicated: 2009 2008 $ million $ million Revenue i 3,772 3,801 Cost of goods sold ii 1,030 1,077 Gross profit 2,742 2,724 Marketing, selling and distribution expenses iii 1,351 1,416 Administrative expenses iv 513 526 Research and development expenses 155 152 Operating profit i 723 630 Net interest payable 40 66 Other finance costs 15 1 Share of results of associates 21 Profitbefore taxation 670 564 Taxation 198 187 Attributable profit forthe year 472 377 i Group revenue and operating profitarederived whollyfromContinuing Operationsand discussed onasegment basisonpages 37 to38.
ii 2009 includes $15m of restructuring and rationalisation expenses and $12m of acquisition related costs 2008 $15m in respect of the utilisation of Plus inventory stepped-up to fair value on acquisition, $18m of restructuring and rationalisation expenses and $8m of acquisition related costs.
iii 2009 includes $7m of acquisition related costs and $10m of restructuring and rationalisation expenses 2008 $7m of acquisition related costs and $3m ofrestructuring and .
iv 2009 includes $7m of acquisition related costs, $17m of restructuring and rationalisation expenses and $66m relating to amortisation of acquisition intangibles and impairments 2008 $31m of acquisition related costs, $13m of restructuring and rationalisation expenses and $51m  intangibles and impairments.
2010Annual Report 34 Transactionaland  The Groups principal markets outside the US are, in order of significance, Continental Europe, UK, Australia and Japan.
Revenues in these markets fluctuate when translated into US Dollars on consolidation.
During the year, the average rates of exchange against the US Dollar used to translate revenues and profits arising in these markets changed compared to the previous year as follows: the Euro weakened from $1.46 to $1.39 -5%, Sterling weakened from $1.84 to $1.56 -15%, the SwissFranc remained flat at $0.92, the AustralianDollar weakened from$0.84 to $0.78 -7% and the Japanese Yen strengthened from103 to 94 9%.
The Groups principal manufacturing locations are in the US Orthopaedics and Endoscopy, Switzerland Orthopaedics and UK Advanced Wound Management and Orthopaedics.
The majority of the Groups selling and distribution subsidiaries around the world purchase finished products fromthese locations.
As a result of currency movements compared with the previous year, purchases fromthe USbecame relatively more expensive.
The Groups policy of purchasing forward a proportion of its currency requirements mitigates the impact of these movements.
Revenue Group revenue decreased by $29m -1% from $3,801m in 2008 to $3,772m in 2009.
Underlying revenue growth was 2%, offset by -3% attributable to unfavourable currency translation.
Orthopaedics revenues decreased by $23m -1%, of which 1% was attributable to underlying growth, offset by -2% due to unfavourable currency translation.
Endoscopy revenues decreased by $9m -1%, of which 1% was attributable to underlying growth, offset by -2% due to unfavourable currency translation.
Advanced Wound Management revenues increased by $3m nil%, of which 6% was attributable to underlying growth, offset by -6% due to unfavourable currency translation.
Amoredetailed analysis is included within the Revenue sections of the individual business segments that followon pages 37 and 38.
Costof goods sold Cost of goods sold decreased by $47m to $1,030m from $1,077m in 2008.
The main drivers of this decrease are continuing focus on cost efficiency, cost effectiveness and the impact of currency.
Other factors contributing to the movement were the decrease of $15m in utilisation of the Plus inventory stepped up to fair value on the acquisition, a decrease of $3m in restructuring and rationalisation expenses, offset by an increase of $4min other acquisition related costs.
Further marginanalysis is included within the Trading profitsections of the individual business segments that followon pages 37 to 38.
Marketing, sellingand distributionexpenses These expenses decreased by $65m to $1,351m from $1,416m in 2008.
The decrease was largely driven by continuing focus on cost management, efficiencies achieved through the Earnings Improvement Programme and the impact of currency.
These were partly offset by an increase in restructuring and  of $7m.
 Administrative expenses decreased by $13m to $513m from $526m in 2008, largely as a result of the focus on cost management and efficiency and the impact of currency.
Other factors contributing to the movement were the decrease of $24m in other acquisition related costs, offset by an increase in the amortisation and impairment charge of intangible assets by $15m and an increase of $4m in restructuring and .
Research and developmentexpenses Expenditure as a percentage of revenue increased by 0.1% to 4.1% in 2009 2008 4.0%.
The Group continues to invest in innovative technologies and products to differentiate itself fromcompetitors.
Operatingprofit Operating profit increased by $93m to $723m from $630m in 2008 comprising, increase of $28m in Orthopaedics, $23m in Endoscopy and $42min Advanced Wound Management.
2010Annual Report 35 InvestorInformation CompanyAccounts GroupAccounts  CorporateGovernance BusinessReview, Descriptionof theGroup Report Statement  Net interestpayable Net interest payable decreased by $26m from $66m in 2008 to $40m in 2009.
This is a consequence of the overall reduction of borrowings within the Group and a reduction in the applicable interest rates.
Otherfinancecost Other finance costs in 2009 were $15m compared to $1m in 2008.
This increase is attributable to a decrease in the expected return on pension plan assets.
Taxation The taxation charge increased by $11mto $198mfrom$187min 2008.
The effective rate of tax was 29.6%, compared with 33.2% in 2008.
The tax charge was reduced by $26m in 2009 2008 $30m as a consequence of restructuring and rationalisation expenses, acquisition related costs, amortisation of acquisition intangibles and impairments.
The effective tax rate was 27.9% 2008 30.6% after adjusting for these items and the tax thereon.
This is a lower rate than expected due to favourable progress in, and resolution of, certain historic issues.
GroupBalance Sheet The followingtable sets out certain balance sheet data forthe years ended indicated: 2009 2008 $ million $ million Non-current assets 2,480 2,523 Current assets 2,071 1,985 Assets held forsale 14 - Total assets 4,565 4,508 Non-current liabilities 1,523 1,841 Current liabilities 863 968 Total liabilities 2,386 2,809 Total equity 2,179 1,699 Total equity and liabilities 4,565 4,508 Non-current assets decreased by $43m to $2,480m from $2,523 in 2008.
Intangible assets and goodwill decreased by $60m of which $112m related to the Plus settlement, $92m to amortisation and impairments and $4m to disposals.
These were offset by $102m of additions, $15m relating to the acquisition of Nucryst and $31m relating to favourable currency translation.
Property, plant and equipment increased by $28m comprising $216m of additions, $30m of favourable currency translation and $6m relating to the acquisition of Nucryst.
This was offset by $206m of depreciation charge, $10m of disposals and $8m of assets transferred to held for sale.
Deferred tax assets decreased by $12min the year, primarilydue to the decrease in post retirement obligations.
Current assets increased by $86m to $2,071m from $1,985m in 2008.
This was due to an increase in inventory of $54m and an increase in cash at bank of $47m.
These increases were partiallyoffset by a reduction in trade and other receivables of $15m.
Non-current liabilities decreased by $318m from $1,841m in 2008 to $1,523m in 2009.
$268m of this decrease was due to the reduction of long-term borrowings.
The net retirement benefit obligation decreased by $28m.
This was due to experience gains on plan assets and liabilities totalling $88m.
These gains were offset by a $47m increase in the defined obligation attributable to changes in actuarial assumptions and $16mof unfavourable currency movements.
Current liabilities decreased by $105m from $968m in 2008 to $863m in 2009.
This was due to a decrease in bank overdrafts and current borrowingsof $70m, a decrease in trade and other payables of $11mand decrease in current tax payable of $25m.
The principal movements were an increase of $472m due to attributable profit, an increase in currency translation and hedging gains of $62m, an increase of $41m relating to actuarial gains on retirement benefit obligations, offset by $10mrelating to deferred taxation and $120mdue to dividends paid during the year.
